Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE PMR
2022-003128-42Phase 3Active
- Sponsor
- Sint Maartenskliniek
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Rituximab with Placebo (2 arms). Primary endpoint: Glucocorticoid-free remission at week 52. Started Dec 2022; status: active.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2022-003128-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003128-42.